Christopher Yea - Aug 17, 2023 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Stock symbol
KALV
Transactions as of
Aug 17, 2023
Transactions value $
-$76,624
Form type
4
Date filed
8/21/2023, 08:06 PM
Previous filing
May 22, 2023
Next filing
Nov 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise +11.5K +30.81% 48.8K Aug 17, 2023 Direct F1
transaction KALV Common Stock Sale -$76.6K -7.14K -14.63% $10.73 41.7K Aug 18, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Options Exercise $0 -1.77K -8.33% $0.00 19.5K Aug 17, 2023 Common Stock 1.77K Direct F1, F4
transaction KALV Restricted Stock Unit Options Exercise $0 -2.43K -10% $0.00 21.9K Aug 17, 2023 Common Stock 2.43K Direct F1, F5
transaction KALV Performance Stock Unit Options Exercise $0 -7.29K -100% $0.00* 0 Aug 17, 2023 Common Stock 7.29K Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and performance stock units ("PSUs"). The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.7280 to $10.8619, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 1/16th of the total RSUs subject to the Award shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, subject to continued service through each vesting date.
F5 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, for a period of three years, subject to continued service through each vesting date.
F6 Each PSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F7 Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Data and Enrollment Metrics goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of August 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.